{
    "nct_id": "NCT06541509",
    "official_title": "A Pilot Clinical Trial Investigating Underlying Mechanisms of Semaglutide Therapy in Heart Failure Patients",
    "inclusion_criteria": "* Age: 20-80 years\n* Presence of heart failure\n* Body-mass index 27 kg/m2 or greater\n* Stable optimally tolerated dosages of heart failure therapies for 3 months\n* N-terminal pro B-type natriuretic peptide levels >350 pg/mL\nHealthy volunteers allowed\nMust have minimum age of 20 Years\nMust have maximum age of 80 Years",
    "exclusion_criteria": "* Presence of type 1 or type 2 diabetes or glycated haemoglobin higher than 6.5%\n* Pregnancy or potential to become pregnant\n* Cancer\n* Liver dysfunction (aspartate aminotransferase and/or alanine aminotransferase > 3 times upper limits of normal or total bilirubin greater than 1.5 times upper limits of normal)\n* Renal dysfunction (estimated glomerular filtration rate less than 25 mL/min/1.73 m2)\n* Hospitalization in the past 3 months for reasons other than heart failure\n* New York Heart Association (NYHA) functional class I or functional class IV symptoms.\n* Prior or planned bariatric surgery\n* Self-reported change in body weight >11 lbs (5 kg) within 3 months before enrollment\n* Acute or chronic infection",
    "miscellaneous_criteria": ""
}